Strong investor demand, significantly oversubscribed
Tranches priced at the lower end of the marketing range
Group’s capital structure and capital cost significantly improved
FY2024 audited accounts confirm preliminary numbers in line with guidance
Q1/2025 sales up +13%, adj. EBITDA surges +28%, margin reaches Vision 2025 target
Sales grow +15% to € 2.3 billion, profitability jumps +23%
FY2024 preliminary numbers in line with capital market guidance published in July 2024
Group adj. EBITDA grows by 23%, in Europe the margin is up +2.1 %pt. (to 22.8%)
Lothes is the first American on Fielmann Group’s Management Board; Demonstrates Company’s Commitment to Empower US Eyewear Customers
Fielmann Group’s price leadership as well as its international expansion lead to +13% growth in the first nine months (organic growth +5%, US acquisitions +8%)
ISS ESG, one of the most renowned rating companies for sustainable and responsible investments, has awarded the Fielmann Group a Prime Status ESG rating in the Healthcare category.
